The guy doing most of the technical talking is Bob. I have not heard him before but he appeared to have a handle on the data.

I find it interesting that this was a topline data analysis yet most of the questions were from the assistants of the assigned analysts. The only name I recognized was Simon from Cowen.

The goal of non-inferiority was met in both trials. Without a major in depth analysis of the data how does one separate the impact of Afrezza from the other drugs taken in the studies?

I think we should let them absorb the studies and then decide whether or not the drug will perform as expected.

Swing